Protection is not guaranteed against this strain
Across the borderlands of Central and East Africa, a strain of Ebola known as Bundibugyo is claiming lives and crossing boundaries, forcing the world's health institutions to confront a familiar and humbling question: whether the tools we have are equal to the threat we face. More than 130 people have died in the Congo and the outbreak has reached Kampala, prompting the WHO to declare a global health emergency. The only licensed Ebola vaccine, Ervebo — partly tested in Kenya and proven against a different strain — now stands at the center of an urgent, unresolved debate about whether partial protection is better than none, and what science, ethics, and speed require of us in the same breath.
- A fast-moving Bundibugyo virus outbreak has killed over 130 people in the DRC and reached Uganda's capital, Kampala, triggering a WHO declaration of international health emergency.
- The only available Ebola vaccine, Ervebo, was built for a different strain — and no one yet knows whether it will protect against Bundibugyo, leaving health officials caught between urgency and uncertainty.
- Gavi has warned that deploying Ervebo against this outbreak would require WHO guidance, further scientific assessment, and genuine informed consent from communities already living through conflict and crisis.
- Scientists are racing to adapt existing vaccine platforms for Bundibugyo, but new doses are six to nine months away — a timeline the outbreak may not respect.
- A coalition of global health bodies, backed by emergency financing funds established after Covid-19, is mobilizing to coordinate response across conflict zones where surveillance and access remain deeply compromised.
A new Ebola outbreak driven by the Bundibugyo virus is spreading through Uganda and the Democratic Republic of Congo, with more than 500 suspected cases and at least 130 deaths reported in Congo alone. Confirmed cases have now reached Kampala, and the outbreak's movement through conflict zones and remote areas has led the World Health Organization to declare a Public Health Emergency of International Concern.
At the center of the response debate is Ervebo, a vaccine partly tested in Kenya and licensed to fight Zaire ebolavirus — a related but distinct strain. The vaccine has proven highly effective against Zaire, reducing cases by 77 percent and deaths by 76 percent in outbreak campaigns, and Gavi maintains a global stockpile of 500,000 doses. But Bundibugyo is different enough that cross-protection remains scientifically unproven. Gavi has been direct: no licensed vaccines exist for this strain, and any deployment of Ervebo would require WHO guidance, further assessment, and informed community consent.
In parallel, scientists are working on adapted vaccine candidates — one using Ervebo's platform modified for Bundibugyo, another built on the ChAdOx technology from Covid-19 vaccines. Neither is ready. Producing viable doses could take six to nine months, a timeline that sits uneasily against an outbreak that is accelerating.
Gavi, WHO, Africa CDC, Unicef, the World Bank, and CEPI are coordinating the response, with emergency financing under evaluation through Gavi's First Response Fund — a mechanism created after Covid-19 that holds the equivalent of over 64 billion Kenyan shillings through 2030 and was recently used to secure vaccines during an mpox outbreak. Health officials are stressing that evidence, speed, and coordination must move together if the spread across East Africa's borders is to be contained.
A new Ebola outbreak is spreading across Uganda and the Democratic Republic of Congo, and health officials are now asking whether a vaccine designed for a different strain of the virus might offer some protection. The outbreak is caused by Bundibugyo virus, a variant distinct from the Zaire strain that existing vaccines were built to fight. More than 500 suspected cases and at least 130 deaths have been reported in the Congo alone, with confirmed cases now appearing in Kampala. The speed and geography of the spread—through conflict zones and remote areas where surveillance is difficult—has prompted the World Health Organization to declare it a Public Health Emergency of International Concern.
The vaccine in question is Ervebo, which was partly tested in Kenya and is already licensed to protect against Zaire ebolavirus. It was developed through international partnerships and has proven remarkably effective against that particular strain. A 2025 study in BMJ Global Health found that outbreak vaccination campaigns reduced Zaire cases by 77 percent and deaths by 76 percent on average. Gavi, the Vaccine Alliance, currently maintains a global stockpile of 500,000 doses of Ervebo, which has been deployed in four outbreak responses in the Congo, including a 2025 campaign that vaccinated more than 47,000 people. Health workers in the region have also received preventive doses.
But here is the central problem: Bundibugyo virus is different enough from Zaire that no one yet knows whether Ervebo will work against it. Gavi has stated plainly that there are currently no licensed vaccines for Bundibugyo disease, and that existing Ebola vaccines in the global stockpile are approved only for Zaire ebolavirus. The organization cautioned that any decision to deploy Ervebo in the current outbreak would require further assessment, guidance from the World Health Organization, and informed consent from affected communities. The evidence on cross-protection between vaccine and virus strain is, as Gavi put it, extremely limited.
Scientists are pursuing other options in parallel. One vaccine candidate uses the same platform as Ervebo but is being adapted specifically for Bundibugyo virus. However, no doses are currently available for trials, and producing them could take six to nine months. Another candidate relies on the ChAdOx platform, which was used in Covid-19 vaccines, though it has not yet undergone animal or human testing for this strain. The timeline is urgent: the outbreak is growing rapidly in both countries, and the spread through conflict-affected and hard-to-reach areas is complicating every aspect of the response.
Gavi is working with the World Health Organization, the Africa Centres for Disease Control and Prevention, Unicef, the World Bank, and the Coalition for Epidemic Preparedness Innovations to assess vaccine needs and accelerate response measures. The organization is also evaluating emergency financing through its First Response Fund, which was established after the Covid-19 pandemic to enable rapid outbreak interventions. The fund has 64.75 billion Kenyan shillings available through 2030. It was recently deployed during an mpox outbreak to secure 500,000 vaccine doses and support a 1.29 billion shilling response operation. As health agencies work to determine whether existing tools can be adapted for the new strain, they are stressing that speed, coordination, and evidence-based decision-making will be critical to preventing further cross-border spread in East Africa.
Notable Quotes
Any decision to use this vaccine in the current outbreak will require further assessments and will occur in accordance with WHO guidance, and deployment would require informed consent from affected communities.— Gavi, the Vaccine Alliance
Outbreak vaccination reduced cases by 77 percent and deaths by 76 percent on average against Zaire strain.— 2025 BMJ Global Health study
The Hearth Conversation Another angle on the story
Why can't they just use the vaccine they already have? It works against Ebola, doesn't it?
It works against one type of Ebola—Zaire. Bundibugyo is a different virus. It's like having a key that opens one lock perfectly but not knowing if it will work on a different lock entirely.
So they have to test it first?
Yes, but carefully. They need to understand whether there's any cross-protection, and they need the communities affected to understand the risks and agree to it. That's not bureaucracy—that's ethics, especially in places already dealing with conflict and distrust.
How long would it take to make a vaccine designed specifically for this strain?
Six to nine months just to produce the first doses. By then, the outbreak could have spread much further. That's the real tension here—the need for speed against the need for evidence.
What happens in the meantime?
They deploy what they have—the Ervebo stockpile—but cautiously, with monitoring. They accelerate work on the adapted candidates. And they focus on the basics: finding cases, isolating patients, protecting health workers. The vaccine is one tool, but it's not the only one.
Is this outbreak worse than previous ones?
It's spreading faster and in harder places to reach. That makes it harder to contain, regardless of what vaccine tools are available.